GMO Financial’s record revenue was 90% trading and financial income as commissions fell 38%

GMO Financial Holdings reported record results for the first nine months of 2026: operating revenue of ¥44.507 billion, operating profit of ¥16.065 billion and profit attributable to owners of ¥10.531 billion. The composition of that revenue was more concentrated than the record headline suggests. Net trading income and financial revenue together were ¥40.102 billion—90.1% of operating revenue. Commission received fell 37.7% to ¥2.148 billion and represented only 4.83% of the total.[1][2][3]

The finding matters because GMO operates securities, foreign-exchange and crypto businesses that can be casually described as commission brokerage. The accounts show a different current model. Revenue depended chiefly on net trading income generated by the securities and FX perimeter and on financial revenue, including income linked to customer deposits and credit transactions. The commission line was shrinking even as total revenue and profit reached records. That is not evidence of customer losses or undisclosed proprietary speculation; it is an accounting map of where reported income sat.[1][2]

The record was not commission-led

Operating revenue increased 15.9% from ¥38.413 billion to ¥44.507 billion. Net trading income rose 18.2% from ¥28.266 billion to ¥33.414 billion, adding ¥5.148 billion. Financial revenue rose 44.5% from ¥4.627 billion to ¥6.688 billion, adding ¥2.061 billion. Those two increases more than offset the ¥1.298 billion decline in commissions and the ¥71 million decline in other operating revenue. Other sales added ¥253 million.[1][2]

Net trading and financial income contributed 90.103% of revenue. Commission received contributed 4.826%. Other sales, largely outside the main securities and crypto reportable segments, contributed 5.0%, while the residual other operating line was negligible. The composition means that a continued decline in commissions could coexist with rising group revenue if spreads, trading conditions and interest-related income remain favorable. It also means the earnings base can react sharply when those conditions reverse.[2]

What 'net trading income' does not prove

The accounting label should not be translated automatically into “GMO traded against customers” or “customer losses became company profit.” In an OTC foreign-exchange or CFD business, net trading income can include spreads, hedging outcomes, inventory management and the aggregate result of customer-facing transactions. The filing does not establish a one-for-one transfer from losing clients, nor does it isolate proprietary risk-taking. Making that leap would exceed the evidence.[1][2]

GMO said over-the-counter FX revenue remained below the prior year because of weakness in the first half, but profitability improved sharply in the third quarter as foreign-exchange volatility rose amid coordinated intervention and comments intended to restrain yen depreciation. CFD revenue remained well above the prior-year level after an exceptionally strong first quarter and drove overall results. The explanation links the trading-income line to market conditions and product economics, not merely transaction count.[1][3]

Financial revenue became a second growth engine

Financial revenue increased by ¥2.061 billion, or 44.5%. GMO attributed the continued increase partly to higher returns on customer-deposit investment as interest rates rose and to solid credit-transaction revenue. That makes the group sensitive not only to trading volatility but also to the rate paid or earned on client-related balances and financing. A broker can therefore benefit from higher rates even when commission pricing is under pressure.[1][3]

Financial expenses also increased, from ¥2.228 billion to ¥3.134 billion. Net operating revenue rose 14.4% to ¥40.677 billion, slightly slower than the 15.9% increase in gross operating revenue. Looking only at the gross financial-revenue line would overstate the benefit because funding costs moved in the same direction. The consolidated income statement provides the necessary bridge from gross categories to net revenue.[2]

Profit rose, but costs rose too

Selling, general and administrative expenses increased from ¥21.855 billion to ¥24.612 billion. Personnel expenses rose by ¥972 million, trading-related expenses by ¥522 million, office expenses by ¥738 million and taxes and dues by ¥298 million. Operating profit nevertheless increased 17.3% to ¥16.065 billion because net operating revenue grew faster than total SG&A in absolute terms. Ordinary profit rose 24.4%, and attributable profit rose 18.2%.[1][2]

The profit result supports the argument that the revenue mix was economically productive during the period. It does not make the mix low-risk. Net trading income can fluctuate with volatility, client behavior, pricing and hedging. Financial revenue can respond to rates and balance growth. Commission income may be less capital-intensive or differently cyclical depending on the product. A record period can contain a concentration that becomes visible only when conditions change.[1][2][3]

The segment view confirms the concentration

The Securities and FX segment generated ¥39.199 billion of external revenue, 88.1% of the group total, and ¥16.374 billion of segment profit. Crypto-asset revenue was ¥3.082 billion with ¥664 million of profit. Other activities generated ¥2.225 billion of revenue and a ¥973 million loss, bringing consolidated operating profit to ¥16.065 billion. The main result was therefore overwhelmingly a securities-and-FX outcome, while crypto remained profitable but much smaller.[3]

Within that dominant segment, the filing’s revenue categories reveal the mechanism. Commission income was split between the Securities and FX and Crypto businesses, while trading income was concentrated principally in Securities and FX. Financial revenue was also concentrated there. Describing the group simply as a brokerage would conceal the spread, trading and balance-sheet components responsible for the record.[2][3]

The comparison that should not be made

It would be wrong to compare GMO’s ¥33.414 billion of net trading income directly with a US broker’s net revenue or with customer trading volume. The amount is neither notional turnover nor gross customer deposits. It is an income-statement result after the company’s trading-related accounting. A take-rate calculation would require a consistent volume denominator and an exact definition of what sits inside the numerator. The public filing reviewed does not provide that reconciliation in the same table.[2]

It would also be wrong to assume the 37.7% commission decline meant customers paid 37.7% less in total. Commission received is one accounting line. Customers may also bear spreads, financing charges or other costs recorded elsewhere. Determining the total customer-cost trend would require product-level prices, volumes and financing. This investigation addresses the company’s revenue mix, not aggregate customer outcomes.[2]

What would show whether the record is repeatable

Future reports could separate net trading income by OTC FX, CFDs, exchange-traded securities and hedging, with consistent volume and revenue-per-volume measures. Financial revenue should be bridged to average client balances, credit balances, gross yield and funding cost. Commission income should be reconciled to trades and fee schedules. Those disclosures would identify whether growth came from more activity, wider spreads, better hedging, higher rates or a change in product mix.[1][2][3]

The current evidence supports a precise conclusion. GMO Financial’s record nine-month revenue was not driven by commissions. Net trading income and financial revenue supplied 90.1% of the total, while commissions fell 37.7% and supplied 4.83%. The company remained profitable and its dominant Securities and FX segment produced the result. The key risk and opportunity therefore lie in the durability of trading and balance-sheet economics, not in a simple rebound of traditional commission brokerage.[1][2][3]

Report an error or submit an update